Investors

Webcast ImageWebcast
Q2 2014 Depomed Earnings Conference Call (Live)
08/06/14 at 4:30 p.m. ET

Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently market four FDA-approved products, Gralise®, Cambia®, Zipsor®, and Lazanda®. We actively seek to expand our product portfolio through in-licensing, acquiring or obtaining co-promotion rights to commercially available products or late-stage product candidates that could be marketed and sold effectively with our existing products through our sales and marketing capability. In addition, Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. We have licensed Acuform technology to six pharmaceutical partners and the technology is currently being used in four marketed drugs, including Gralise.

The following are abbreviated descriptions of our products:

Gralise® (gabapentin), a once-daily product for the management of postherpetic neuralgia, Cambia®(diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older,  Zipsor® (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain in adults, and Lazanda® (fentanyl) nasal spray CII for the  management of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving and who are tolerant to regular opioid therapy for their underlying persistent cancer pain.  See Important Safety Information for Gralise and the black box warnings for CambiaZipsor, and Lazanda.

Recent News> MORE
DateTitle 
07/25/14Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014Printer Friendly Version
07/17/14Depomed Announces District Court Order in ANDA LitigationPrinter Friendly Version
07/16/14Depomed Announces Appointment of Srinivas G. Rao, MD, PhD, as Chief Medical OfficerPrinter Friendly Version
Upcoming and Recent Events> MORE
DateTitle
08/06/14
4:30 p.m. ET
Q2 2014 Depomed Earnings Conference Call
06/24/14
11:30 a.m. ET
Depomed at JMP Securities Healthcare Conference
LocationThe Westin New York Grand Central
New York City, NY US
06/18/14
3:35 p.m. ET
Depomed at Wells Fargo Healthcare Conference
LocationThe InterContinental
Boston, MA US

DEPO (Common Stock)

Exchange
NASDAQ CM
Price
$10.80
Change (%)
 + 0.85 (8.54%)
Volume
1,587,478
Market Cap
$626,302,800

Data as of 08/01/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Powered By EDGAR Online, Inc.